Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756686 | 0.88 | KDR (0.48) | AURKAAURKBRPS6KB1GRM5MEN1 | |
| SCHEMBL6759794 | 0.76 | AURKA (0.46) | AURKAAURKBRPS6KB1KDR | |
| SCHEMBL6756827 | 0.73 | RAB9A (0.48) | AURKAAURKBRPS6KB1MEN1KMT2A | |
| SCHEMBL148468 | 0.71 | ALDH1A1 (0.58) | MEN1KMT2A | |
| SCHEMBL677656 | 0.71 | KMT2A (0.53) | MEN1KMT2A | |
| SCHEMBL6754353 | 0.71 | MAPT (0.42) | AURKARPS6KB1MEN1KMT2AKDR | |
| SCHEMBL6759896 | 0.70 | HDAC3 (0.48) | AURKARPS6KB1 | |
| SCHEMBL6755621 | 0.69 | KMT2A (0.46) | GRM5MEN1KMT2A | |
| SCHEMBL6809571 | 0.69 | KMT2A (0.49) | GRM5MEN1KMT2ABRAF | |
| SCHEMBL6833155 | 0.69 | CNR1 (0.47) | GRM5MEN1KMT2ABRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | AURKA 553/4885AURKB 1376/4885RPS6KB1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.